Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.31
- Piotroski Score 3.00
- Grade Buy
- Symbol (VIVO)
- Company Meridian Bioscience, Inc.
- Price $33.97
- Changes Percentage (0%)
- Change -$0
- Day Low $33.95
- Day High $34.01
- Year High $34.38
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
- Last Earnings 01/24/2019
- Ex-Dividend for 5/16 Dividend 02/01/2019
- Dividend Payable 02/14/2019
- Today N/A
- Next Earnings (Estimated) 05/04/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.61
- Trailing P/E Ratio 21.086281812539
- Forward P/E Ratio 21.086281812539
- P/E Growth 21.086281812539
- Net Income $42.46 M
Income Statement
Quarterly
Annual
Latest News of VIVO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Skip new CBS reality show 'The Summit'; You can just watch 'Survivor' instead
In the era of reality competition series, CBS introduces "The Summit," a mountain-climbing show with a $1 million prize. However, it falls short with convoluted rules, physical challenges, and lacks t...
By USA Today | 1 day ago -
US Catholic diocese agrees to pay $323m to child sexual abuse survivors
The Rockville Centre diocese in New York settled with over 530 victims for $323m in a new bankruptcy deal. The settlement avoided failure and sets an example for other dioceses facing similar challeng...
By The Guardian | 1 day ago -
NFL survivor pool Week 4: Best picks, predictions, advice and strategy
The first three weeks of the NFL season were historic with consecutive underdog wins. Unpredictability continues in Week 4 survivor pools. Teams like the Steelers, Titans, and Jets are favored picks t...
By USA Today | 1 day ago
